Resources from the same session
131MO - Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: analysis of vital registration data from the WHO Mortality Database between 2000 and 2017
Presenter: Philip Baum
Session: Mini Oral session 1
Resources:
Abstract
Slides
81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated Results
Presenter: Chao Lyu
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
108MO - Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Presenter: Marina Garassino
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
82MO - Risk-adjusted mortality rates as a quality proxy outperform volume in lung cancer surgery - a new perspective on hospital centralization using national population-based data
Presenter: Philip Baum
Session: Mini Oral session 1
Resources:
Abstract
Slides
109MO - Respect the Middle Lobe: Perioperative Survival of Bilobectomy Compared to Lobectomy and Pneumonectomy
Presenter: Andrew Li
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
157MO - Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
Presenter: Marta Casarrubios
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
172MO - Analysis of comutations in DNA damage repair (DDR) related pathways with immunotherapeutic biomarkers in Chinese lung cancer patients
Presenter: Jun Li
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant of 131MO, 81MO and 108MO
Presenter: Leah Backhus
Session: Mini Oral session 1
Resources:
Slides
Webcast
Invited Discussant of 157MO and 172MO
Presenter: Keith Kerr
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast